Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 63
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for NBIX

Stock Name	Neurocrine Biosciences Inc
Ticker	NBIX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US64125C1099
LEI	549300FECER0XBN49756

Show aggregate NBIX holdings

News associated with NBIX

Canaccord Genuity Group Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $160.00: Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price raised by Canaccord Genuity Group from $158.00 to $160.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently commented on NBIX. Needham & Company LLC raised shares of Neurocrine Biosciences from […] - 2025-05-09 08:37:11
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up on Analyst Upgrade: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) shares gapped up prior to trading on Tuesday after Royal Bank of Canada raised their price target on the stock from $137.00 to $145.00. The stock had previously closed at $109.75, but opened at $123.00. Royal Bank of Canada currently has an outperform rating on the stock. […] - 2025-05-07 06:10:42
Investors Purchase Large Volume of Neurocrine Biosciences Put Options (NASDAQ:NBIX): Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) was the target of some unusual options trading on Monday. Investors purchased 3,005 put options on the company. This represents an increase of 325% compared to the average volume of 707 put options. Wall Street Analysts Forecast Growth NBIX has been the subject of a number of […] - 2025-05-06 05:10:52
2,425 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Acquired by Marshall Wace LLP: Marshall Wace LLP acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,425 shares of the company’s stock, valued at approximately $331,000. A number of other institutional investors have also […] - 2025-05-05 08:03:00
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $158.00 at Canaccord Genuity Group: Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective reduced by research analysts at Canaccord Genuity Group from $163.00 to $158.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 47.33% […] - 2025-04-30 06:00:51
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $161.14 Average Price Target from Analysts: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two brokerages that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating on the company. The average 12 month […] - 2025-04-28 06:06:49
Wednesday's ETF with Unusual Volume: FLSP: The Franklin Systematic Style Premia ETF is seeing unusually high volume in afternoon trading Wednesday, with over 1.1 million shares traded versus three month average volume of about 30,000. Shares of FLSP were up about 0.5% on the day. Components of that ETF with the highest - 2025-04-16 16:12:59
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Royal Bank of Canada: Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities research analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating in a research note issued on Monday, MarketBeat.com reports. The brokerage currently has a $137.00 price objective on the stock, down from their prior price objective of $138.00. […] - 2025-04-16 05:56:51
UBS Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $137.00: Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target reduced by UBS Group from $154.00 to $137.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock. A number of other analysts have also weighed in on NBIX. Royal Bank of Canada cut their target price […] - 2025-04-07 05:38:48
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $165.38 Consensus Price Target from Brokerages: Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has issued a strong buy recommendation on […] - 2025-04-03 06:06:54
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by American Century Companies Inc.: American Century Companies Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 49.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,523 shares of the company’s stock after selling 88,727 shares during the period. American Century Companies […] - 2025-04-02 07:54:55
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Corient Private Wealth LLC: Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,927 shares of the company’s stock after purchasing an additional 3,094 shares during the quarter. Corient Private […] - 2025-03-27 09:14:52
Envestnet Portfolio Solutions Inc. Purchases 278 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,868 shares of the company’s stock after acquiring an additional 278 shares […] - 2025-03-27 09:14:51
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $184.00 at JPMorgan Chase & Co.: Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target hoisted by JPMorgan Chase & Co. from $183.00 to $184.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock. Several other research analysts also recently commented on NBIX. Barclays increased their price objective on Neurocrine Biosciences from […] - 2025-03-27 07:47:06
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com: Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday. A number of other analysts have also recently issued reports on NBIX. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences […] - 2025-03-14 06:12:43
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by M&T Bank Corp: M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the company’s stock after buying an additional 1,322 shares during the quarter. […] - 2025-03-12 08:19:05
Victory Capital Management Inc. Sells 14,309 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Victory Capital Management Inc. decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 189,896 shares of the company’s stock after selling 14,309 shares during the period. Victory Capital Management […] - 2025-03-11 08:16:52
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Charles Schwab Investment Management Inc.: Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 762,557 shares of the company’s stock after buying an additional 15,266 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $104,089,000 as […] - 2025-03-10 11:50:03
Smartleaf Asset Management LLC Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Smartleaf Asset Management LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 37.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 538 shares of the company’s stock after purchasing an additional 146 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Neurocrine Biosciences were worth $74,000 as of its […] - 2025-03-10 09:10:55
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by IFP Advisors Inc: IFP Advisors Inc raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,020 shares of the company’s stock after purchasing an additional 137 shares during the period. IFP Advisors Inc’s holdings […] - 2025-03-03 09:35:15
First Horizon Advisors Inc. Has $118,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 865 shares of the company’s stock after selling 142 shares during the period. First Horizon Advisors Inc.’s holdings in Neurocrine Biosciences were worth $118,000 at the end […] - 2025-02-27 09:05:01
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,442 shares of the company’s stock after selling 6,148 shares during the period. Vontobel Holding […] - 2025-02-19 09:15:16
Neurocrine Biosciences (NASDAQ:NBIX) Earns Hold Rating from Analysts at Deutsche Bank Aktiengesellschaft: Deutsche Bank Aktiengesellschaft initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Tuesday, MarketBeat reports. The brokerage issued a hold rating and a $138.00 target price on the stock. NBIX has been the subject of a number of other research reports. Needham & Company LLC restated a “hold” […] - 2025-02-14 09:04:49
State of Alaska Department of Revenue Cuts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): State of Alaska Department of Revenue cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,535 shares of the company’s stock after selling 200 shares during the quarter. State of Alaska Department […] - 2025-02-12 10:44:45
Brokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $169.20: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-three research firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on […] - 2025-02-12 08:12:57
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $163.00 at Guggenheim: Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock. NBIX has been the subject of several other research reports. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from […] - 2025-02-11 07:12:48
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 4.9% After Analyst Downgrade: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report)’s share price traded down 4.9% on Monday after Guggenheim lowered their price target on the stock from $165.00 to $163.00. Guggenheim currently has a buy rating on the stock. Neurocrine Biosciences traded as low as $116.48 and last traded at $116.60. 1,568,535 shares changed hands during mid-day […] - 2025-02-11 06:10:42
Royal Bank of Canada Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $148.00: Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently has a sector perform rating on the stock. A number of other research firms have also recently weighed in on NBIX. Canaccord Genuity Group lowered […] - 2025-02-10 16:58:49
Canaccord Genuity Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $163.00: Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective trimmed by Canaccord Genuity Group from $172.00 to $163.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James restated an “outperform” rating and […] - 2025-02-10 16:58:47
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by abrdn plc: abrdn plc boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.8% during the fourth quarter, Holdings Channel reports. The firm owned 156,574 shares of the company’s stock after buying an additional 20,150 shares during the quarter. abrdn plc’s holdings in Neurocrine Biosciences were worth $21,372,000 at the end of […] - 2025-02-07 09:28:53

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) NBIX holdings

Date	Number of NBIX Shares Held	Base Market Value of NBIX Shares	Local Market Value of NBIX Shares	Change in NBIX Shares Held	Change in NBIX Base Value	Current Price per NBIX Share Held	Previous Price per NBIX Share Held
2025-05-08 (Thursday)	47,469	USD 5,578,557	USD 5,578,557	0	USD -194,148	USD 117.52	USD 121.61
2025-05-07 (Wednesday)	47,469	USD 5,772,705	USD 5,772,705	0	USD 127,692	USD 121.61	USD 118.92
2025-05-06 (Tuesday)	47,469	USD 5,645,013	USD 5,645,013	0	USD 435,290	USD 118.92	USD 109.75
2025-05-05 (Monday)	47,469	USD 5,209,723	USD 5,209,723	0	USD 3,323	USD 109.75	USD 109.68
2025-05-02 (Friday)	47,469	USD 5,206,400	USD 5,206,400	0	USD 146,679	USD 109.68	USD 106.59
2025-05-01 (Thursday)	47,469	USD 5,059,721	USD 5,059,721	0	USD -52,216	USD 106.59	USD 107.69
2025-04-30 (Wednesday)	47,469	USD 5,111,937	USD 5,111,937	0	USD 21,361	USD 107.69	USD 107.24
2025-04-29 (Tuesday)	47,469	USD 5,090,576	USD 5,090,576	0	USD 37,026	USD 107.24	USD 106.46
2025-04-28 (Monday)	47,469	USD 5,053,550	USD 5,053,550	0	USD -12,816	USD 106.46	USD 106.73
2025-04-25 (Friday)	47,469	USD 5,066,366	USD 5,066,366	0	USD 46,045	USD 106.73	USD 105.76
2025-04-24 (Thursday)	47,469	USD 5,020,321	USD 5,020,321	0	USD 120,571	USD 105.76	USD 103.22
2025-04-23 (Wednesday)	47,469	USD 4,899,750	USD 4,899,750	165	USD 87,041	USD 103.22	USD 101.74
2025-04-22 (Tuesday)	47,304	USD 4,812,709	USD 4,812,709	0	USD 50,142	USD 101.74	USD 100.68
2025-04-21 (Monday)	47,304	USD 4,762,567	USD 4,762,567	0	USD -33,113	USD 100.68	USD 101.38
2025-04-18 (Friday)	47,304	USD 4,795,680	USD 4,795,680	0	USD 0	USD 101.38	USD 101.38
2025-04-17 (Thursday)	47,304	USD 4,795,680	USD 4,795,680	0	USD 60,550	USD 101.38	USD 100.1
2025-04-16 (Wednesday)	47,304	USD 4,735,130	USD 4,735,130	0	USD 186,377	USD 100.1	USD 96.16
2025-04-15 (Tuesday)	47,304	USD 4,548,753	USD 4,548,753	0	USD 60,076	USD 96.16	USD 94.89
2025-04-14 (Monday)	47,304	USD 4,488,677	USD 4,488,677	0	USD 190,163	USD 94.89	USD 90.87
2025-04-11 (Friday)	47,304	USD 4,298,514	USD 4,298,514	0	USD 7,095	USD 90.87	USD 90.72
2025-04-10 (Thursday)	47,304	USD 4,291,419	USD 4,291,419	-1,320	USD -341,476	USD 90.72	USD 95.28
2025-04-09 (Wednesday)	48,624	USD 4,632,895	USD 4,632,895	0	USD 376,350	USD 95.28	USD 87.54
2025-04-08 (Tuesday)	48,624	USD 4,256,545	USD 4,256,545	-165	USD -293,029	USD 87.54	USD 93.25
2025-04-07 (Monday)	48,789	USD 4,549,574	USD 4,549,574	-165	USD -132,876	USD 93.25	USD 95.65
2025-04-04 (Friday)	48,954	USD 4,682,450	USD 4,682,450	-825	USD -709,113	USD 95.65	USD 108.31
2025-04-02 (Wednesday)	49,779	USD 5,391,563	USD 5,391,563	0	USD 65,210	USD 108.31	USD 107
2025-04-01 (Tuesday)	49,779	USD 5,326,353	USD 5,326,353	1,433	USD -20,715	USD 107	USD 110.6
2025-03-31 (Monday)	48,346	USD 5,347,068	USD 5,347,068	-489	USD -179,101	USD 110.6	USD 113.16
2025-03-28 (Friday)	48,835	USD 5,526,169	USD 5,526,169	0	USD -41,021	USD 113.16	USD 114
2025-03-27 (Thursday)	48,835	USD 5,567,190	USD 5,567,190	0	USD -21,976	USD 114	USD 114.45
2025-03-26 (Wednesday)	48,835	USD 5,589,166	USD 5,589,166	0	USD -84,484	USD 114.45	USD 116.18
2025-03-25 (Tuesday)	48,835	USD 5,673,650	USD 5,673,650	0	USD 28,324	USD 116.18	USD 115.6
2025-03-24 (Monday)	48,835	USD 5,645,326	USD 5,645,326	0	USD 179,713	USD 115.6	USD 111.92
2025-03-21 (Friday)	48,835	USD 5,465,613	USD 5,465,613	1,238	USD 226,611	USD 111.92	USD 110.07
2025-03-20 (Thursday)	47,597	USD 5,239,002	USD 5,239,002	0	USD -11,423	USD 110.07	USD 110.31
2025-03-19 (Wednesday)	47,597	USD 5,250,425	USD 5,250,425	0	USD 29,034	USD 110.31	USD 109.7
2025-03-18 (Tuesday)	47,597	USD 5,221,391	USD 5,221,391	0	USD -85,675	USD 109.7	USD 111.5
2025-03-17 (Monday)	47,597	USD 5,307,066	USD 5,307,066	0	USD 35,698	USD 111.5	USD 110.75
2025-03-14 (Friday)	47,597	USD 5,271,368	USD 5,271,368	-2,544	USD -193,500	USD 110.75	USD 108.99
2025-03-13 (Thursday)	50,141	USD 5,464,868	USD 5,464,868	0	USD -4,011	USD 108.99	USD 109.07
2025-03-12 (Wednesday)	50,141	USD 5,468,879	USD 5,468,879	0	USD 92,761	USD 109.07	USD 107.22
2025-03-11 (Tuesday)	50,141	USD 5,376,118	USD 5,376,118	0	USD -183,015	USD 107.22	USD 110.87
2025-03-10 (Monday)	50,141	USD 5,559,133	USD 5,559,133	0	USD -108,806	USD 110.87	USD 113.04
2025-03-07 (Friday)	50,141	USD 5,667,939	USD 5,667,939	-318	USD -16,772	USD 113.04	USD 112.66
2025-03-06 (Thursday)	50,459	USD 5,684,711	USD 5,684,711	0	USD -60,046	USD 112.66	USD 113.85
2025-03-05 (Wednesday)	50,459	USD 5,744,757	USD 5,744,757	0	USD 37,340	USD 113.85	USD 113.11
2025-03-04 (Tuesday)	50,459	USD 5,707,417	USD 5,707,417	-159	USD -87,332	USD 113.11	USD 114.48
2025-03-03 (Monday)	50,618	USD 5,794,749	USD 5,794,749	0	USD -214,620	USD 114.48	USD 118.72
2025-02-28 (Friday)	50,618	USD 6,009,369	USD 6,009,369	0	USD 61,248	USD 118.72	USD 117.51
2025-02-27 (Thursday)	50,618	USD 5,948,121	USD 5,948,121	0	USD -4,050	USD 117.51	USD 117.59
2025-02-26 (Wednesday)	50,618	USD 5,952,171	USD 5,952,171	0	USD 85,545	USD 117.59	USD 115.9
2025-02-25 (Tuesday)	50,618	USD 5,866,626	USD 5,866,626	318	USD -124,607	USD 115.9	USD 119.11
2025-02-24 (Monday)	50,300	USD 5,991,233	USD 5,991,233	0	USD -79,474	USD 119.11	USD 120.69
2025-02-21 (Friday)	50,300	USD 6,070,707	USD 6,070,707	0	USD 230,374	USD 120.69	USD 116.11
2025-02-20 (Thursday)	50,300	USD 5,840,333	USD 5,840,333	0	USD 93,055	USD 116.11	USD 114.26
2025-02-19 (Wednesday)	50,300	USD 5,747,278	USD 5,747,278	-159	USD -3,534	USD 114.26	USD 113.97
2025-02-18 (Tuesday)	50,459	USD 5,750,812	USD 5,750,812	0	USD -52,982	USD 113.97	USD 115.02
2025-02-17 (Monday)	50,459	USD 5,803,794	USD 5,803,794	0	USD 0	USD 115.02	USD 115.02
2025-02-14 (Friday)	50,459	USD 5,803,794	USD 5,803,794	0	USD -93,349	USD 115.02	USD 116.87
2025-02-13 (Thursday)	50,459	USD 5,897,143	USD 5,897,143	477	USD 40,252	USD 116.87	USD 117.18
2025-02-12 (Wednesday)	49,982	USD 5,856,891	USD 5,856,891	159	USD 35,073	USD 117.18	USD 116.85
2025-02-11 (Tuesday)	49,823	USD 5,821,818	USD 5,821,818	636	USD -21,844	USD 116.85	USD 118.805
2025-02-10 (Monday)	49,187	USD 5,843,662	USD 5,843,662	0	USD -187,648	USD 118.805	USD 122.62
2025-02-07 (Friday)	49,187	USD 6,031,310	USD 6,031,310	0	USD -1,371,825	USD 122.62	USD 150.51
2025-02-06 (Thursday)	49,187	USD 7,403,135	USD 7,403,135	0	USD -33,939	USD 150.51	USD 151.2
2025-02-05 (Wednesday)	49,187	USD 7,437,074	USD 7,437,074	0	USD -60,009	USD 151.2	USD 152.42
2025-02-04 (Tuesday)	49,187	USD 7,497,083	USD 7,497,083	0	USD 114,114	USD 152.42	USD 150.1
2025-02-03 (Monday)	49,187	USD 7,382,969	USD 7,382,969	0	USD -84,601	USD 150.1	USD 151.82
2025-01-31 (Friday)	49,187	USD 7,467,570	USD 7,467,570	0	USD -72,305	USD 151.82	USD 153.29
2025-01-30 (Thursday)	49,187	USD 7,539,875	USD 7,539,875	0	USD 128,378	USD 153.29	USD 150.68
2025-01-29 (Wednesday)	49,187	USD 7,411,497	USD 7,411,497	0	USD -1,476	USD 150.68	USD 150.71
2025-01-28 (Tuesday)	49,187	USD 7,412,973	USD 7,412,973	0	USD 123,951	USD 150.71	USD 148.19
2025-01-27 (Monday)	49,187	USD 7,289,022	USD 7,289,022	0	USD -26,561	USD 148.19	USD 148.73
2025-01-24 (Friday)	49,187	USD 7,315,583	USD 7,315,583	0	USD 56,566	USD 148.73	USD 147.58
2025-01-23 (Thursday)	49,187	USD 7,259,017	USD 7,259,017	0	USD 40,333	USD 147.58	USD 146.76
2025-01-22 (Wednesday)	49,187	USD 7,218,684	USD 7,218,684
2025-01-21 (Tuesday)	49,187	USD 7,175,400	USD 7,175,400
2025-01-20 (Monday)	49,187	USD 7,046,530	USD 7,046,530
2025-01-17 (Friday)	49,187	USD 7,046,530	USD 7,046,530
2025-01-16 (Thursday)	48,551	USD 6,890,358	USD 6,890,358
2025-01-15 (Wednesday)	47,915	USD 6,830,762	USD 6,830,762
2025-01-14 (Tuesday)	47,915	USD 6,684,622	USD 6,684,622
2025-01-13 (Monday)	47,915	USD 6,853,282	USD 6,853,282
2025-01-10 (Friday)	47,915	USD 6,751,224	USD 6,751,224
2025-01-09 (Thursday)	48,233	USD 6,690,399	USD 6,690,399
2025-01-09 (Thursday)	48,233	USD 6,690,399	USD 6,690,399
2025-01-09 (Thursday)	48,233	USD 6,690,399	USD 6,690,399
2025-01-08 (Wednesday)	48,233	USD 6,690,399	USD 6,690,399
2025-01-08 (Wednesday)	48,233	USD 6,690,399	USD 6,690,399
2025-01-08 (Wednesday)	48,233	USD 6,690,399	USD 6,690,399
2025-01-02 (Thursday)	48,869	USD 6,737,080	USD 6,737,080	175	USD 63,080	USD 137.86	USD 137.06
2024-12-30 (Monday)	48,694	USD 6,674,000	USD 6,674,000	-5,480	USD -312,279	USD 137.06	USD 128.96
2024-12-10 (Tuesday)	54,174	USD 6,986,279	USD 6,986,279	0	USD -8,668	USD 128.96	USD 129.12
2024-12-09 (Monday)	54,174	USD 6,994,947	USD 6,994,947	0	USD 53,091	USD 129.12	USD 128.14
2024-12-06 (Friday)	54,174	USD 6,941,856	USD 6,941,856	0	USD 93,179	USD 128.14	USD 126.42
2024-12-05 (Thursday)	54,174	USD 6,848,677	USD 6,848,677	0	USD -71,510	USD 126.42	USD 127.74
2024-12-04 (Wednesday)	54,174	USD 6,920,187	USD 6,920,187	0	USD 124,600	USD 127.74	USD 125.44
2024-12-03 (Tuesday)	54,174	USD 6,795,587	USD 6,795,587	0	USD -24,378	USD 125.44	USD 125.89
2024-12-02 (Monday)	54,174	USD 6,819,965	USD 6,819,965	0	USD -46,590	USD 125.89	USD 126.75
2024-11-29 (Friday)	54,174	USD 6,866,555	USD 6,866,555	0	USD 8,668	USD 126.75	USD 126.59
2024-11-28 (Thursday)	54,174	USD 6,857,887	USD 6,857,887	0	USD 0	USD 126.59	USD 126.59
2024-11-27 (Wednesday)	54,174	USD 6,857,887	USD 6,857,887	0	USD -71,509	USD 126.59	USD 127.91
2024-11-26 (Tuesday)	54,174	USD 6,929,396	USD 6,929,396	0	USD 43,339	USD 127.91	USD 127.11
2024-11-25 (Monday)	54,174	USD 6,886,057	USD 6,886,057	0	USD 79,094	USD 127.11	USD 125.65
2024-11-22 (Friday)	54,174	USD 6,806,963	USD 6,806,963	0	USD 35,213	USD 125.65	USD 125
2024-11-21 (Thursday)	54,174	USD 6,771,750	USD 6,771,750	0	USD 92,638	USD 125	USD 123.29
2024-11-20 (Wednesday)	54,174	USD 6,679,112	USD 6,679,112	0	USD 225,363	USD 123.29	USD 119.13
2024-11-19 (Tuesday)	54,174	USD 6,453,749	USD 6,453,749	0	USD 81,803	USD 119.13	USD 117.62
2024-11-18 (Monday)	54,174	USD 6,371,946	USD 6,371,946	-2,595	USD -838,285	USD 117.62	USD 127.01
2024-11-12 (Tuesday)	56,769	USD 7,210,231	USD 7,210,231	0	USD 72,097	USD 127.01	USD 125.74
2024-11-08 (Friday)	56,769	USD 7,138,134	USD 7,138,134	-173	USD 78,465	USD 125.74	USD 123.98
2024-11-07 (Thursday)	56,942	USD 7,059,669	USD 7,059,669	0	USD -75,164	USD 123.98	USD 125.3
2024-11-06 (Wednesday)	56,942	USD 7,134,833	USD 7,134,833	0	USD 214,672	USD 125.3	USD 121.53
2024-11-05 (Tuesday)	56,942	USD 6,920,161	USD 6,920,161	0	USD 56,942	USD 121.53	USD 120.53
2024-11-04 (Monday)	56,942	USD 6,863,219	USD 6,863,219	0	USD -95,663	USD 120.53	USD 122.21
2024-11-01 (Friday)	56,942	USD 6,958,882	USD 6,958,882	0	USD 110,468	USD 122.21	USD 120.27
2024-10-31 (Thursday)	56,942	USD 6,848,414	USD 6,848,414	0	USD -231,185	USD 120.27	USD 124.33
2024-10-30 (Wednesday)	56,942	USD 7,079,599	USD 7,079,599	0	USD 463,508	USD 124.33	USD 116.19
2024-10-29 (Tuesday)	56,942	USD 6,616,091	USD 6,616,091	0	USD -569	USD 116.19	USD 116.2
2024-10-28 (Monday)	56,942	USD 6,616,660	USD 6,616,660	0	USD 6,833	USD 116.2	USD 116.08
2024-10-25 (Friday)	56,942	USD 6,609,827	USD 6,609,827	0	USD 31,887	USD 116.08	USD 115.52
2024-10-24 (Thursday)	56,942	USD 6,577,940	USD 6,577,940	0	USD 25,055	USD 115.52	USD 115.08
2024-10-23 (Wednesday)	56,942	USD 6,552,885	USD 6,552,885	0	USD -96,802	USD 115.08	USD 116.78
2024-10-22 (Tuesday)	56,942	USD 6,649,687	USD 6,649,687	0	USD 11,958	USD 116.78	USD 116.57
2024-10-21 (Monday)	56,942	USD 6,637,729	USD 6,637,729	-173	USD -102,412	USD 116.57	USD 118.01
2024-10-18 (Friday)	57,115	USD 6,740,141	USD 6,740,141

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NBIX by Blackrock for IE00BDZVHG35

Show aggregate share trades of NBIX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-04-23 BUY 165 103.220* 119.22
2025-04-10 SELL -1,320 90.720* 121.41 Profit of 160,263 on sale
2025-04-08 SELL -165 87.540* 122.10 Profit of 20,147 on sale
2025-04-07 SELL -165 93.250* 122.44 Profit of 20,202 on sale
2025-04-04 SELL -825 95.650* 122.75 Profit of 101,270 on sale
2025-04-01 BUY 1,433 107.000* 123.12
2025-03-31 SELL -489 110.600* 123.27 Profit of 60,278 on sale
2025-03-21 BUY 1,238 111.920* 123.98
2025-03-14 SELL -2,544 110.750* 124.93 Profit of 317,833 on sale
2025-03-07 SELL -318 113.040* 126.08 Profit of 40,093 on sale
2025-03-04 SELL -159 113.110* 126.69 Profit of 20,144 on sale
2025-02-25 BUY 318 115.900* 127.54
2025-02-19 SELL -159 114.260* 128.28 Profit of 20,397 on sale
2025-02-13 BUY 477 116.870* 129.33
2025-02-12 BUY 159 117.180* 129.57
2025-02-11 BUY 636 116.850* 129.84
2025-01-02 BUY 175 137.860* 123.46
2024-12-30 SELL -5,480 137.060* 123.05 Profit of 674,317 on sale
2024-11-18 SELL -2,595 117.620* 120.21 Profit of 311,938 on sale
2024-11-08 SELL -173 125.740* 119.33 Profit of 20,643 on sale
2024-10-21 SELL -173 116.570* 0.00
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-04-23	BUY	165	103.220*	119.22
2025-04-10	SELL	-1,320	90.720*	121.41 Profit of 160,263 on sale
2025-04-08	SELL	-165	87.540*	122.10 Profit of 20,147 on sale
2025-04-07	SELL	-165	93.250*	122.44 Profit of 20,202 on sale
2025-04-04	SELL	-825	95.650*	122.75 Profit of 101,270 on sale
2025-04-01	BUY	1,433	107.000*	123.12
2025-03-31	SELL	-489	110.600*	123.27 Profit of 60,278 on sale
2025-03-21	BUY	1,238	111.920*	123.98
2025-03-14	SELL	-2,544	110.750*	124.93 Profit of 317,833 on sale
2025-03-07	SELL	-318	113.040*	126.08 Profit of 40,093 on sale
2025-03-04	SELL	-159	113.110*	126.69 Profit of 20,144 on sale
2025-02-25	BUY	318	115.900*	127.54
2025-02-19	SELL	-159	114.260*	128.28 Profit of 20,397 on sale
2025-02-13	BUY	477	116.870*	129.33
2025-02-12	BUY	159	117.180*	129.57
2025-02-11	BUY	636	116.850*	129.84
2025-01-02	BUY	175	137.860*	123.46
2024-12-30	SELL	-5,480	137.060*	123.05 Profit of 674,317 on sale
2024-11-18	SELL	-2,595	117.620*	120.21 Profit of 311,938 on sale
2024-11-08	SELL	-173	125.740*	119.33 Profit of 20,643 on sale
2024-10-21	SELL	-173	116.570*	0.00

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NBIX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-05-09	365,532	73	523,045	69.9%
2025-05-08	627,921	244	1,175,097	53.4%
2025-05-07	713,469	2,722	1,117,874	63.8%
2025-05-06	1,400,867	7,030	2,532,763	55.3%
2025-05-05	296,619	121	644,954	46.0%
2025-05-02	365,240	2,717	878,865	41.6%
2025-05-01	334,909	1,718	414,538	80.8%
2025-04-30	184,719	78	452,373	40.8%
2025-04-29	188,845	2,237	268,765	70.3%
2025-04-28	240,716	57	398,177	60.5%
2025-04-25	383,434	2,042	564,857	67.9%
2025-04-24	365,832	195	488,339	74.9%
2025-04-23	458,700	190	910,605	50.4%
2025-04-22	348,645	324	835,216	41.7%
2025-04-21	395,831	361	658,514	60.1%
2025-04-17	457,575	124	678,132	67.5%
2025-04-16	965,353	168	1,358,855	71.0%
2025-04-15	379,427	1,823	668,183	56.8%
2025-04-14	450,911	249	754,056	59.8%
2025-04-11	333,520	203	674,091	49.5%
2025-04-10	472,023	315	628,440	75.1%
2025-04-09	602,330	304	1,006,299	59.9%
2025-04-08	436,875	162	790,249	55.3%
2025-04-07	674,398	421	1,003,463	67.2%
2025-04-04	539,933	385	892,094	60.5%
2025-04-03	376,704	99	768,738	49.0%
2025-04-02	234,959	215	551,498	42.6%
2025-04-01	280,101	30	636,763	44.0%
2025-03-31	216,215	308	411,408	52.6%
2025-03-28	265,011	80	324,522	81.7%
2025-03-27	234,011	41	308,200	75.9%
2025-03-26	305,665	215	394,495	77.5%
2025-03-25	314,222	86	480,625	65.4%
2025-03-24	273,417	1,005	391,306	69.9%
2025-03-21	332,958	6	436,521	76.3%
2025-03-20	210,692	23	342,216	61.6%
2025-03-19	175,559	72	288,223	60.9%
2025-03-18	202,506	165	360,593	56.2%
2025-03-17	212,919	102	305,435	69.7%
2025-03-14	163,942	14,843	330,867	49.5%
2025-03-13	178,672	7,541	288,437	61.9%
2025-03-12	201,638	171	467,323	43.1%
2025-03-11	231,365	248	763,188	30.3%
2025-03-10	214,090	558	359,059	59.6%
2025-03-07	251,531	5,013	472,743	53.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE